Welcome to our dedicated page for Smith & Nephew SEC filings (Ticker: SNN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides access to Smith & Nephew plc (SNN) regulatory disclosures filed with the U.S. Securities and Exchange Commission, primarily through Form 6-K current reports for foreign private issuers. These filings give investors structured insight into the company’s capital structure, strategy, acquisitions and transactions by senior management.
Smith & Nephew uses Form 6-K to report a range of information, including announcements about its RISE strategy and related 2028 financial targets for revenue growth, trading profit, free cash flow and post-tax return on invested capital. Other 6-Ks detail portfolio rationalisation plans, guidance for upcoming financial years, and information on Capital Markets Day events where management presents strategic and product updates.
Filings also include voting rights and capital disclosures, setting out the total issued share capital, treasury shares and the number of voting rights that shareholders should use when assessing notification thresholds under applicable transparency rules. Separate TR-1 notifications, reproduced within 6-Ks, report major holdings changes by institutional investors such as BlackRock, Inc., including the percentage of voting rights attached to shares and through financial instruments.
Additional 6-K reports provide Market Abuse Regulation-compliant notifications of transactions by persons discharging managerial responsibilities (PDMRs) and persons closely associated with them. These cover purchases of ordinary shares and American Depositary Shares, participation in dividend reinvestment and employee stock purchase plans, and vesting of restricted share awards, giving a view of insider dealing activity around SNN securities.
Investors can also find transaction-related disclosures, such as the acquisition of Integrity Orthopaedics and its Tendon Seam™ rotator cuff repair technology, including headline deal terms, strategic rationale within the Sports Medicine portfolio and comments from management. By combining real-time EDGAR updates with AI-powered summaries, this page helps users navigate Smith & Nephew’s 6-Ks, understand the implications of voting rights and insider transactions, and quickly grasp the strategic content of narrative announcements without reading every paragraph in full.
Smith & Nephew delivered stronger full-year 2025 results, with revenue rising to $6,164m from $5,810m and operating profit increasing to $794m from $657m. Attributable profit grew to $625m, lifting basic earnings per share to 72.1¢ from 47.2¢.
Growth was broad-based: Orthopaedics revenue reached $2,437m, Sports Medicine & ENT $1,934m, and Advanced Wound Management $1,793m. Established Markets generated $5,161m of revenue and Emerging Markets $1,003m, with US revenue at $3,306m.
Cash generation was robust, with net cash from operating activities of $1,285m. The company invested $433m in capital expenditure and paid equity dividends of $330m, while also spending $502m on share repurchases. Year-end cash and cash equivalents were $553m, and net debt excluding leases was $2,543m.
Deloitte issued unqualified opinions on both the financial statements and internal control over financial reporting. A key audit focus was the valuation of the excess and obsolescence provision for US orthopaedics inventory, reflecting judgement around future product demand.
Smith+Nephew plc reports that its Chief Executive Officer, Deepak Nath, will join the Board of Reckitt Benckiser Group plc as an independent Non-Executive Director with effect from 1 April 2026. The appointment is disclosed in line with UK Listing Rule 6.4.9R(2).
Smith+Nephew is a global medical technology business focused on repairing, regenerating and replacing soft and hard tissue. It employs around 17,000 people, operates in more than 100 countries and generated annual sales of $6.2 billion in 2025 across Orthopaedics, Sports Medicine & ENT and Advanced Wound Management.
Smith & Nephew plc has updated investors on its voting rights and share capital. As at 28 February 2026, the company had 877,724,845 ordinary shares of US20¢ each in issue, including 27,835,540 shares held in treasury. Because treasury shares do not carry voting rights, shareholders have a total of 849,889,305 voting shares to use as the denominator when assessing whether they must notify the regulator of their holdings or changes in their stake.
Smith+Nephew delivered a strong 2025, with revenue rising to $6,164 million from $5,810 million, an underlying growth of 5.3%. Trading profit grew 15.5% to $1,211 million, lifting the trading margin to 19.7%, while operating profit increased 20.7% to $794 million.
Earnings improved sharply, with EPS up 52.8% to 72.1¢ and EPSA up 21.0% to 102.0¢. Free cash flow jumped 52.5% to $840 million, supporting a $500 million share buyback and a 4.3% dividend increase to 39.1¢ per share.
The company completed its 12-Point Plan, expanded adjusted ROIC to 8.3%, and launched its new RISE strategy with 2028 targets including 6–7% organic revenue CAGR and free cash flow above $1 billion. For 2026, it targets around 6% underlying revenue growth, trading profit of about $1.3 billion, free cash flow around $800 million, and adjusted ROIC above 10%, alongside integrating the $225 million Integrity Orthopaedics acquisition.
Smith+Nephew reported stronger fourth quarter and full-year 2025 results, showing broad-based growth and better profitability. Full-year revenue reached $6,164 million, up 6.1% from 2024, with underlying revenue growth of 5.3% and all three business units above 5% underlying growth.
Trading profit rose to $1,211 million, up 15.5%, lifting the trading margin to 19.7%. Basic EPS increased to 72.1 cents, while adjusted EPS climbed 21.0% to 102.0 cents. Free cash flow improved sharply to $840 million, helped by better working capital, and adjusted ROIC rose to 8.3%.
The company returned $500 million through share buybacks and raised the total 2025 dividend by 4.3% to 39.1 cents per share. For 2026, management targets around 6% underlying revenue growth, trading profit of about $1.3 billion including the Integrity Orthopaedics deal, around $800 million free cash flow and adjusted ROIC above 10%.
Smith+Nephew, a global medical technology company, will announce its results for the full year ended 31 December 2025 on Monday, 2 March 2026 at 7.00am GMT / 2.00am EST. A conference call for financial analysts will follow at 8.30am GMT / 3.30am EST.
The company, which generated annual sales of $5.8 billion in 2024, operates in more than 100 countries with around 18,000 employees. Its portfolio focuses on orthopaedics, sports medicine and ENT, and advanced wound management.
Smith & Nephew plc filed a Form 6-K providing a block listing six monthly return for several employee share schemes for the period from 1 August 2025 to 31 January 2026.
The filing shows no changes in unallotted securities for the Global Share Plan 2010, the 2012 and 2022 ShareSave and International ShareSave plans. Under the Global Share Plan 2020, 14,695 securities were issued or allotted during the period, reducing the unallotted balance under that scheme to 388,563 shares.
Smith & Nephew plc has updated its voting rights and share capital. As at 31 January 2026, the company’s total issued share capital comprises 877,724,845 ordinary shares of US20¢ each, including 27,912,707 ordinary shares held in treasury.
Because treasury shares do not carry voting rights, the company’s issued share capital with voting rights consists of 849,812,138 ordinary shares, each carrying one vote. Shareholders are advised to use this voting share figure as the denominator when assessing whether they must notify holdings or changes under the FCA’s Disclosure Guidance and Transparency Rules.
Smith & Nephew plc reported that several senior leaders purchased its American Depositary Shares on the New York Stock Exchange as part of the Company’s Employee Stock Purchase Plan. The financial instrument is described as Smith & Nephew plc SPON ADR American Depositary Shares (ADS) with ISIN US83175M2052.
On 2026-01-16, these purchases were made at a price of $25.9 per ADS. Reported participants included Craig Gaffin (President, Global Orthopaedics) with a volume of 206.79536, Deepak Nath (Chief Executive Officer) with a volume of 410,10498, Paul Connolly (President, Global Operations) with a volume of 410.10498, and Scott Schaffner (President, Sports Medicine) with a volume of 242.58803, each noted as a single transaction.
Smith+Nephew has completed its acquisition of US-based Integrity Orthopaedics, the early-stage commercial developer of the Tendon Seam™ rotator cuff repair system. Tendon Seam™ is designed to significantly reduce re-tear rates and improve outcomes for patients undergoing rotator cuff repair.
The company paid an initial cash consideration of US$225 million, with additional performance-based payments of up to US$225 million over the next five years. Smith+Nephew states that this acquisition supports its RISE strategy to accelerate growth through strategic investment and portfolio leadership and is intended to be an important step toward becoming the global leader in Sports Medicine. Smith+Nephew generated $5.8 billion of sales in 2024 across more than 100 countries.